Dyslipidemia is an increase in blood lipids. The excessive increase in levels of insulin may also lead to dyslipidemia.
Subtopics
LDL Cholesterol | HDL Cholesterol | NON-HDL Cholesterol | High Sensitivity C-Reactive Protein for Risk Assessment | Stratification of Dyslipidemia Risk | Advanced Lipoprotein Testing | Drugs for Treatment of Blood Lipoprotein Abnormalities
Market Statistics:
The global dyslipidemia drug market was worth US$ 11.8 billion in 2018 and is expected to grow at a CAGR of 3.5% from 2019 to 2027.
North America is the leading contributor to the dyslipidemia medications market. According to the Centers for Disease Control and Prevention (CDC), over 95 million adults in the United States (55% of the population) had total cholesterol levels greater than 200 mg/dL as of 2016. Furthermore, total cholesterol levels higher than 240 mg/dL affect an estimated 29 million adults in the United States.
ALSO READ Cardiologist Clinical Cardiology Heart Diseases Hypertension Electrocardiography Cardio-Oncology Interventional Cardiology Nuclear Cardiology Cardiac Nursing Pediatric Cardiology Stroke Cardiac Surgery Thrombosis Heart Arrhythmia Valvular Heart Disease Pulmonology and Cardiology Atherosclerosis Sports Cardiology Cardiac Imaging Vascular Biology Cardiology Case Reports Geriatric Cardiology Cardiovascular Pharmacology Robotic Cardiac Surgery Cardiac Regeneration Dyslipidemia Cardiovascular disease Congestive Heart Failure Acute Coronary Syndrome
Tags
Cardiology Conferences 2023
Cardiac Nursing Conferences
Cardiology Conferences 2023
Cardiology Conferences 2023 Asia
Stroke Conferences
Cardiology Conferences 2023 Europe
Cardiology Conferences 2023 Australia
Cardiology Conferences 2023 Canada
Arrhythmia Conferences
Heart Congress Japan
Cardiology Conferences 2022 USA
Pediatric Cardiology Conferences
Clinical Cardiology Conferences